Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02633059 · OUTCOME

Progression Free Survival (Phase II)

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2024-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 3 years

What was measured

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.

Groups in this outcome

Phase II and MTD

6 MTD and 16 phase II accruals

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase II and MTD22

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase II and MTD3.8Not reported2.27.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.2
        upper Limit
        7.4
        value
        3.8
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    6 MTD and 16 phase II accruals
    id
    OG000
    title
    Phase II and MTD
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 3 years
title
Progression Free Survival (Phase II)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice